Guangdong Hengrui Pharmaceutical Co., Ltd

Pharma

Guangzhou, Guangdong, China · Est. 2000

Guangdong Hengrui Pharmaceutical is a Chinese biopharmaceutical company focused on the research, development, and commercialization of innovative drugs.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

11 drugs in development

Approved1

Phase 33

Phase 29

Phase 12

Preclinical1

By Therapeutic Area

top 6

Respiratory

737%

Immunology

632%

Hematology

211%

Ophthalmology

15%

Nephrology

15%

Oncology

15%

R&D Momentum

64/100

Pipeline Velocity

48/100

Trial Completion Rate

94/100

Pipeline Concentration

26/100

Pipeline Freshness

89/100

Strategic Signals

↗Active in Ophthalmology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 3, 2026

Completed

A Phase Ib/II Study to Investigate the Safety、PK and PD of SHR-1819 in Children and Adolescents With Moderate-to-severe Atopic Dermatitis

Jul 3, 2026

Completed

Safety, Tolerability and Pharmacokinetics of HRS-9813 After Multiple Oral Administration in Healthy Subjects-A Phase I Clinical Study

Earlier

Mar 5, 2026TrialA Study to Evaluate SHR-1139 Injection in Patients With Pyoderma Gangrenosum

Mar 1, 2026TrialA Study of SHR-2173 in Participants With Systemic Lupus Erythematosus

Feb 1, 2026TrialA Study of SHR-2173 in Participants With Primary IgA Nephropathy

Jan 19, 2026TrialA Phase II Trial of SHR-3045 Injection in Patients With Rheumatoid Arthritis

Jan 9, 2026TrialA Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis

Dec 31, 2025TrialPhase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

3 more events

Dec 1, 2025TrialA Study on the Bioavailability of SHR-1819 Injection Administered Subcutaneously Using Different Injection Devices in Healthy Subjects

Dec 1, 2025TrialA Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of SHR-1139 in Patients With Moderate-to-severe Active Ulcerative Colitis

Dec 1, 2025TrialA Phase III Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Founded2000

HQGuangzhou, Guangdong, China

Websitehengrui.com.cn

Therapeutic Focus

OncologyCardiovascularAnti-infection

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Dermatology(1 drug)

—

Dermatology(1 drug)

Hematology(2 drugs)

—

Hematology(2 drugs)

Immunology(6 drugs)

—

Immunology(6 drugs)

Nephrology(1 drug)

—

Nephrology(1 drug)

Oncology(1 drug)

—

Oncology(1 drug)

Ophthalmology(1 drug)

—

Ophthalmology(1 drug)

Respiratory(7 drugs)

—

Respiratory(7 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)